Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | RORC | P51449 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | RORA | P35398 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | HRH2 | P25021 | 2/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18189154 | 0.82 | MMP1 (0.40) | RORCALDH1A1RORAKDM1AMMP1 | |
| SCHEMBL18189287 | 0.76 | ALDH1A1 (0.43) | RORCALDH1A1RORAEPHX2 | |
| SCHEMBL18189414 | 0.73 | CD274 (0.48) | TSHRSCN9AHRH2HRH1POLB | |
| SCHEMBL18189253 | 0.73 | CHRM1 (0.41) | RORCALDH1A1RORAADAM17EPHX2 | |
| SCHEMBL30426010 | 0.72 | RORC (0.42) | RORCALDH1A1RORA | |
| SCHEMBL18189589 | 0.72 | RORC (0.42) | RORCALDH1A1RORA | |
| SCHEMBL18189245 | 0.72 | RAB9A (0.42) | RORCALDH1A1RORAPOLB | |
| SCHEMBL18189237 | 0.71 | ALDH1A1 (0.48) | TSHRRORCALDH1A1RORAHSD17B10 | |
| SCHEMBL20110745 | 0.70 | RORC (0.46) | RORCALDH1A1RORA | |
| SCHEMBL30426609 | 0.70 | RORC (0.40) | SCN9ARORCALDH1A1RORAADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392092-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2020-12-17 | — | — | US | claimed |
| US-10647689-B2 | Apelin receptor agonists and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-05-12 | — | — | US | claimed |
| WO-2016176473-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | SANFORD-BURNHAM MEDICAL RESEARC INSTITUTE (US) | 2016-11-03 | — | — | WO | claimed |
| US-12071414-B2 | Apelin receptor agonists and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-08-27 | — | — | US | disclosed |
| US-20230339872-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-10-26 | — | — | US | disclosed |
| US-20230339872-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-10-26 | — | — | US | disclosed |
| US-20230339872-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-10-26 | — | — | US | disclosed |
| US-11673873-B2 | Apelin receptor agonists and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673873-B2 | Apelin receptor agonists and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673873-B2 | Apelin receptor agonists and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-06-13 | — | — | US | disclosed |
| US-20200392092-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2020-12-17 | — | — | US | disclosed |
| US-20200392092-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2020-12-17 | — | — | US | disclosed |
| US-10647689-B2 | Apelin receptor agonists and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-05-12 | — | — | US | disclosed |
| US-10647689-B2 | Apelin receptor agonists and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180118698-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2018-05-03 | — | — | US | disclosed |
| US-20180118698-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2018-05-03 | — | — | US | disclosed |
| US-20180118698-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2018-05-03 | — | — | US | disclosed |
| WO-2016176473-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | SANFORD-BURNHAM MEDICAL RESEARC INSTITUTE (US) | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339872-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | APLNR, APMAP, EDNRA | TSHR 215/4885SCN9A 3723/4885RORC 2141/4885 |
| US-20200392092-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | APLNR, APMAP, EDNRA | TSHR 215/4885SCN9A 3723/4885RORC 2141/4885 |
| US-11673873-B2 | Apelin receptor agonists and methods of use thereof | APLNR, APMAP, EDNRA | TSHR 215/4885SCN9A 3723/4885RORC 2141/4885 |
| US-20180118698-A1 | APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF | APLNR, APMAP, EDNRA | TSHR 215/4885SCN9A 3723/4885RORC 2141/4885 |
| US-10647689-B2 | Apelin receptor agonists and methods of use thereof | APLNR, APMAP, EDNRA | TSHR 215/4885SCN9A 3723/4885RORC 2141/4885 |
| US-12071414-B2 | Apelin receptor agonists and methods of use thereof | APLNR, APMAP, EDNRA | TSHR 215/4885SCN9A 3723/4885RORC 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.